Molecular structure of ICRF-193, CAS Number: 21416-68-2
ICRF-193 (CAS 21416-68-2)
See product citations (7)
Alternate Names:
4,4′-(1,2-Dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione
Application:
ICRF-193 is a bisdioxopiperazine which induces apoptosis and erythroid differentiation
CAS Number:
21416-68-2
Purity:
≥95%
Molecular Weight:
282.30
Molecular Formula:
C12H18N4O4
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
ICRF-193, a bisdioxopiperazine, is a catalytic noncleavable complex-forming inhibitor of DNA Topo II (topoisomerase II) that does not produce protein-linked DNA strand breaks. This compound may act to induce erythroid differentiation and apoptosis. Mechanistic studies suggest that ICRF-193 affects the caspase-3 activation/cleavage pathway of cell growth and associates with ATR-dependent inhibition of polo-like kinase (plk) 1 kinase activity and a decrease in cyclin B1 phosphorylation. ICRF-193 is an inhibitor of Topo II beta.
ICRF-193 (CAS 21416-68-2) References
- Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha. | Patel, S., et al. 2000. Mol Pharmacol. 58: 560-8. PMID: 10953049
- The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. | Hasinoff, BB., et al. 2001. Mol Pharmacol. 59: 453-61. PMID: 11179439
- Decreased thymosin beta4 in apoptosis induced by a variety of antitumor drugs. | Iguchi, K., et al. 1999. Biochem Pharmacol. 57: 1105-11. PMID: 11230797
- ICRF-193, a catalytic inhibitor of DNA topoisomerase II, inhibits re-entry into the cell division cycle from quiescent state in mammalian cells. | Hossain, MS., et al. 2002. Genes Cells. 7: 285-94. PMID: 11918672
- ATR enforces the topoisomerase II-dependent G2 checkpoint through inhibition of Plk1 kinase. | Deming, PB., et al. 2002. J Biol Chem. 277: 36832-8. PMID: 12147700
- DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193. | Hajji, N., et al. 2003. Mutat Res. 530: 35-46. PMID: 14563529
- Cell cycle-dependent DNA damage signaling induced by ICRF-193 involves ATM, ATR, CHK2, and BRCA1. | Park, I. and Avraham, HK. 2006. Exp Cell Res. 312: 1996-2008. PMID: 16630610
- ICRF-193, an anticancer topoisomerase II inhibitor, induces arched telophase spindles that snap, leading to a ploidy increase in fission yeast. | Nakazawa, N., et al. 2016. Genes Cells. 21: 978-93. PMID: 27458047
- DNA binding activity of the proximal C-terminal domain of rat DNA topoisomerase IIβ is involved in ICRF-193-induced closed-clamp formation. | Kawano, S., et al. 2020. PLoS One. 15: e0239466. PMID: 32960919
- Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity. | Bavlovič Piskáčková, H., et al. 2021. Sci Rep. 11: 4456. PMID: 33627707
- Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions. | Jirkovská, A., et al. 2021. J Med Chem. 64: 3997-4019. PMID: 33750129
- Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo. | Kollárová-Brázdová, P., et al. 2021. Clin Sci (Lond). 135: 1897-1914. PMID: 34318878
- ICRF-193, an inhibitor of topoisomerase II, demonstrates that DNA replication in sperm nuclei reconstituted in Xenopus egg extracts does not require chromatin decondensation. | Takasuga, Y., et al. 1995. Exp Cell Res. 217: 378-84. PMID: 7698239
- ICRF-193 modifies etoposide-induced apoptosis in thymocytes. | Tanimoto, C., et al. 1995. Acta Med Okayama. 49: 281-6. PMID: 8770236
- ICRF-193, a catalytic inhibitor of DNA topoisomerase II, delays the cell cycle progression from metaphase, but not from anaphase to the G1 phase in mammalian cells. | Iwai, M., et al. 1997. FEBS Lett. 406: 267-70. PMID: 9136899
Inhibitor of:
ACTR5, ANKRD13D, BRF2, CELF5, CGI-99_2700060E02Rik, CPN cat, CPSF4L, CRSP150_CRSP2, CST9L, DDX59, ELL3, Elongin A3, ENSMUSG00000073257, Gvin1, hCAP-D2, HELIC1, Histone cluster 3 H2ba, hnRNP U, Hus1, INO80C, INTS2, LEO1, LOC100040682, Mad 4, MEI1, NIPBL, Pol II-H, POLR2G, Polr2j, POLR2L, POLR3GL, RBM15, RBM29, RBMX2, Rec8, RPAIN, Rrn3, SSBP2, SWAP, SYCE1, TAF I p110_TAF I p95, TAF II p100, TAF II p135, TAFII-28, TFIIA-γ, TFIID, TFIIF RAP 74, TFIIIB, TFIIIB90, TFIIIC35, THAP2, THAP9, Topo II beta, UBF, and ZSCAN23.Activator of:
Pol II-H, Pol III RPC39, SMC4, TDP2, and WDR12.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ICRF-193, 1 mg | sc-200889 | 1 mg | $341.00 | |||
ICRF-193, 5 mg | sc-200889A | 5 mg | $927.00 |